October 25, 2024 article Open access Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy New England Journal of Medicine DOI: 10.1056/nejmoa2410316 Full text (OA) OpenAlex Authors 0 Author list not loaded yet. Cited by 16 stored of 195 Search Sort Most cited Newest Oldest Patent citations Title Any typearticle review book-chapter conference-paper preprint dissertation book dataset other Any fieldAgricultural and Biological Sciences Arts and Humanities Biochemistry, Genetics and Molecular Biology Business, Management and Accounting Chemical Engineering Chemistry Computer Science Decision Sciences Dentistry Earth and Planetary Sciences Economics, Econometrics and Finance Energy Engineering Environmental Science Health Professions Immunology and Microbiology Materials Science Mathematics Medicine Neuroscience Nursing Pharmacology, Toxicology and Pharmaceutics Physics and Astronomy Psychology Social Sciences Veterinary Open access Evidence-based guidelines for the diagnosis and management of adult-onset IgA vasculitis 2026 Nature Reviews Rheumatology review Medicine Vasculitis and related conditions Open access 0 citations Individualised treatment effects of corticosteroids in IgA nephropathy 2026 EBioMedicine article Medicine Renal Diseases and Glomerulopathies Open access 0 citations Differing effects of Nefecon and Sparsentan in a patient with recurrent IgA nephropathy post-kidney transplantation 2026 Clinical Kidney Journal article Medicine Renal Diseases and Glomerulopathies Open access 1 citations Shifting From Systemic to Precision‐Targeted Complement Therapies: Opportunities and Hurdles 2026 European Journal of Immunology article Immunology and Microbiology Complement system in diseases Open access 1 citations Measuring effectiveness in immunoglobulin A nephropathy: what are we looking for? 2026 Clinical Kidney Journal article Medicine Renal Diseases and Glomerulopathies Open access 0 citations Complement inhibitors and B cell–modifying agents for IgA nephropathy—a Kidney Disease: Improving Global Outcomes (KDIGO) commentary 2026 Kidney International article Medicine Renal Diseases and Glomerulopathies Open access 4 citations Simultaneous or sequential treatment of IgA nephropathy - specific disease drivers and non-specific consequences of nephron loss? 2026 Clinical Kidney Journal article Medicine Renal Diseases and Glomerulopathies Open access 0 citations Microscopic hematuria in IgA nephropathy: a biomarker of disease activity 2026 Clinical Kidney Journal article Medicine Renal Diseases and Glomerulopathies Open access 7 citations IgA-Nephropathie – Update 2025 Die Nephrologie article Medicine Renal Diseases and Glomerulopathies 0 citations Iptacopan für die IgA-Nephropathie 2025 Die Nephrologie article Medicine Renal Diseases and Glomerulopathies 0 citations Complement-Mediated Kidney Diseases: Role of Alternative Pathway in Glomerular Inflammation 2025 Kidney International Reports article Immunology and Microbiology Complement system in diseases Open access 3 citations A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy 2025 New England Journal of Medicine article Medicine Renal Diseases and Glomerulopathies 51 citations The 2025 KDIGO IgA nephropathy guideline update: an ERA Immunonephrology Working Group perspective 2025 Clinical Kidney Journal article Medicine Renal Diseases and Glomerulopathies Open access 10 citations Alternative pathway–mediated tubular complement activation in human proteinuric kidney diseases: a proof-of-concept study 2025 Clinical Kidney Journal article Immunology and Microbiology Complement system in diseases Open access 4 citations RNA-based therapeutic opportunities for the treatment of kidney diseases 2025 Nature Reviews Nephrology review Biochemistry, Genetics and Molecular Biology RNA Interference and Gene Delivery 8 citations Treatment of patients with IgA nephropathy: a call for a new paradigm 2025 Kidney International article Medicine Renal Diseases and Glomerulopathies Open access 76 citations 16 results References 5 Search Sort Most cited Newest Oldest Patent citations Title Any typearticle review book-chapter conference-paper preprint dissertation book dataset other Any fieldAgricultural and Biological Sciences Arts and Humanities Biochemistry, Genetics and Molecular Biology Business, Management and Accounting Chemical Engineering Chemistry Computer Science Decision Sciences Dentistry Earth and Planetary Sciences Economics, Econometrics and Finance Energy Engineering Environmental Science Health Professions Immunology and Microbiology Materials Science Mathematics Medicine Neuroscience Nursing Pharmacology, Toxicology and Pharmaceutics Physics and Astronomy Psychology Social Sciences Veterinary Open access Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial 2023 The Lancet article Medicine Renal Diseases and Glomerulopathies Open access 334 citations Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial 2023 The Lancet article Medicine Renal Diseases and Glomerulopathies Open access 305 citations Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy 2022 Kidney International article Medicine Renal Diseases and Glomerulopathies Open access 226 citations Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis 2021 American Journal of Kidney Diseases article Medicine Renal Diseases and Glomerulopathies Open access cited by 6 patents 106 citations How I Treat IgA Nephropathy 2022 Clinical Journal of the American Society of Nephrology article Medicine Renal Diseases and Glomerulopathies Open access 14 citations 5 results